The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
Open accessAbstract
BACKGROUND: Since anecdotal series and small, prospective, controlled trials suggest that mycophenolate mofetil may be effective for treating lupus nephritis, larger trials are desirable. METHODS: We conducted a 24-week randomized, open-label, noninferiority trial comparing oral mycophenolate mofetil (initial dose, 1000 mg per day, increased to 3000 mg per day) with monthly intravenous cyclophosphamide (0.5 g per square meter of body-surface area, increased to 1.0 g per square meter) as induction therapy for active lupus nephritis. A change to the alternative regimen was allowed at 12 weeks in patients who did not have an early response. The study protocol specified adjunctive care and the use and tapering of corticosteroids. The primary end point was complete remission at 24 weeks (normalization of abnormal renal measurements and maintenance of baseline normal measurements). A secondary end point was partial remission at 24 weeks. RESULTS: Of 140 patients recruited, 71 were randomly assigned to receive mycophenolate mofetil and 69 were randomly assigned to receive cyclophosphamide. At 12 weeks, 56 patients receiving mycophenolate mofetil and 42 receiving cyclophosphamide had satisfactory early responses. In the intention-to-treat analysis, 16 of the 71 patients (22.5 percent) receiving mycophenolate mofetil and 4 of the 69 patients receiving cyclophosphamide (5.8 percent) had complete remission, for an absolute difference of 16.7 percentage points (95 percent confidence interval, 5.6 to 27.9 percentage points; P=0.005), meeting the prespecified criteria for noninferiority and demonstrating the superiority of mycophenolate mofetil to cyclophosphamide. Partial remission occurred in 21 of the 71 patients (29.6 percent) and 17 of the 69 patients (24.6 percent), respectively (P=0.51). Three patients assigned to cyclophosphamide died, two during protocol therapy. Fewer severe infections and hospitalizations but more diarrhea occurred among those receiving mycophenolate. CONCLUSIONS: In this 24-week trial, mycophenolate mofetil was more effective than intravenous cyclophosphamide in inducing remission of lupus nephritis and had a more favorable safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Austin, H. A., Klippel, J. H., Balow, J. E., Le Riche, N. G. H., Steinberg, A. D., Plotz, P. H., & Decker, J. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603063141004 · Cited by 1,185
Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis
Chan, T. M., Li, F. K., Tang, C. S. O., Wong, R. W. S., Fang, G. X., Ji, Y. L., Lau, C. S., Wong, A. K. M., Tong, M. K. L., Chan, K. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431604 · Cited by 954
Boumpas, D. T., Austin, H. A., Balow, J. E., Vaughan, E. M., Yarboro, C. H., Klippel, J. H., & Steinberg, A. D. (1992) · The Lancet · doi:10.1016/0140-6736(92)92292-n · Cited by 823
Sequential Therapies for Proliferative Lupus Nephritis
Contreras, G., Pardo, V., Leclercq, B., Lenz, O., Tozman, E., O'Nan, P., & Roth, D. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031855 · Cited by 818
Gourley, M. F., Austin III, H. A., Scott, D., Yarboro, C. H., Vaughan, E. M., Muir, J., Boumpas, D. T., Klippel, J. H., Balow, J. E., & Steinberg, A. D. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00003 · Cited by 607
Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis
(2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440513 · Cited by 539
Chan, T.-M., Tse, K.-C., Tang, C. S.-O., Mok, M.-Y., & Li, F.-K. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004080686 · Cited by 479
Houssiau, F. A., Vasconcelos, C., D'Cruz, D., Sebastiani, G. D., de Ramon Garrido, E., Danieli, M. G., Abramovicz, D., Blockmans, D., Mathieu, A., Direskeneli, H., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20666 · Cited by 391
Factors predictive of outcome in severe lupus nephritis
Korbet, S. M., Lewis, E. J., Schwartz, M. M., Reichlin, M., Evans, J., & Rohde, R. D. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70262-9 · Cited by 374
Steinberg, A. D., & Steinberg, S. C. (1991) · Arthritis & Rheumatism · doi:10.1002/art.1780340803 · Cited by 348
Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans
Dooley, M. A., Hogan, S., Jennette, C., Falk, R., & for the Glomerular Disease Collaborative Network (1997) · Kidney International · doi:10.1038/ki.1997.162 · Cited by 341
Self-citationIllei, G. G., Takada, K., Parkin, D., Austin, H. A., Crane, M., Yarboro, C. H., Vaughan, E. M., Kuroiwa, T., Danning, C. L., Pando, J., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10142 · Cited by 329
Alarc�n, G. S., McGwin, Jr., Bastian, H. M., Roseman, J., Lisse, J., Fessler, B. J., Friedman, A. W., Reveille, J. D., & LUMINA Study Group (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200104)45:2<191::aid-anr173>3.0.co;2-2 · Cited by 325
Boumpas, D. T., Austin, H. A., Fessler, B. J., Balow, J. E., Klippel, J. H., & Lockshin, M. D. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-12-199506150-00009 · Cited by 303
Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide
Ioannidis, J. P. A., Boki, K. A., Katsorida, M. E., Drosos, A. A., Skopouli, F. N., Boletis, J. N., & Moutsopoulos, H. M. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00832.x · Cited by 231
Mycophenolate Mofetil Therapy in Lupus Nephritis: Clinical Observations
DOOLEY, M. A., COSIO, F. G., NACHMAN, P. H., FALKENHAIN, M. E., HOGAN, S. L., FALK, R. J., & HEBERT, L. A. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v104833 · Cited by 230
Self-citationPrognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity
Barr, R. G. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg345 · Cited by 206
Neylan, J. F. (1997) · Transplantation · doi:10.1097/00007890-199711150-00008 · Cited by 181
Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents
Karim, M. Y. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/41.8.876 · Cited by 153
Cortés-Hernández, J., Ordi‐Ros, J., Labrador‐Horrillo, M., Segarra-Medrano, A., Tovar, J. L., Balada, E., & Vilardell, M. (2003) · Lupus · doi:10.1191/0961203303lu340oa · Cited by 83
Equivalence trials in SLE research: issues to consider
Kim, M., Buyon, J. P., Petri, M., Skovron, M. L., & Shore, R. E. (1999) · Lupus · doi:10.1191/096120399680411308 · Cited by 20
Self-citation
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Hahn, B. H., McMahon, M. A., Wilkinson, A., Wallace, W. D., Daikh, D. I., FitzGerald, J. D., Karpouzas, G. A., Merrill, J. T., Wallace, D. J., Yazdany, J., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21664 · Cited by 1,463
Self-citationRovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez‐Guerrero, J., Maciuca, R., Zhang, D., Garg, J. P., Brunetta, P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,461
Self-citationMycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Isenberg, D., Jayne, D., Li, L.-S., Mysler, E., Sa[Combining Acute Accent]nchez-Guerrero, J., Solomons, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008101028 · Cited by 1,118
Self-citationBertsias, G. K., Tektonidou, M., Amoura, Z., Aringer, M., Bajema, I., Berden, J. H. M., Boletis, J., Cervera, R., Dörner, T., Doria, A., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201940 · Cited by 1,007
Metadata
- Authors
- Ginzler, E. M., Dooley, M. A., Aranow, C., Kim, M. Y., Buyon, J., Merrill, J. T., Petri, M., Gilkeson, G. S., Wallace, D. J., Weisman, M. H., & Appel, G. B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-24
- Volume
- 353
- Issue
- 21
- Pages
- 2219-2228
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160388191
- Cited by
- 1,128
- References
- 22
- FWCI
- 40.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.